Related Experiment Videos
[Lymphadenectomy in colorectal carcinoma]
C A Nieroda1, M W Arnold, E Barbera-Guillem
1Department of Surgery, Arthus G. James Cancer Hospital and Research Institute, Ohio State University, Columbus, USA.
Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen
|September 17, 1998
Summary
This study introduces immune corrective surgery (ICS) to combat colorectal cancer recurrence by removing hidden micrometastases and correcting immune responses. ICS significantly improved survival rates in patients with localized colorectal cancer.
Area of Science:
- Oncology
- Immunology
- Surgical Innovation
Context:
- Colorectal cancer recurrence affects approximately 50% of patients with localized disease.
- Recurrence is often due to undetected micrometastases or hematogenic spread.
- Current surgical techniques may not eliminate all microscopic tumor deposits.
Purpose:
- To develop and evaluate a novel surgical approach, immune corrective surgery (ICS), to address micrometastases and immune dysregulation in colorectal cancer.
- To investigate the efficacy of selective lymphadenectomy targeting TAA-immune complexes for reducing tumor recurrence.
- To assess the impact of ICS on long-term patient survival.
Summary:
- Radioimmunoguided surgery (RIGS) was enhanced with immune corrective surgery (ICS) involving selective lymphadenectomy.
- ICS targets lymph nodes with tumor-associated antigen (TAA)-immune complexes, detected using radiolabeled antibodies.
- This approach aims to correct detrimental B cell responses and enhance anti-tumor T cell immunity.
Impact:
- Immune corrective surgery (ICS) demonstrated a statistically significant increase in 5-year survival rates for stage I, II, and III colorectal cancer patients.
- The study suggests extending colorectal cancer surgery to specific regions to remove hidden micrometastases and optimize postoperative immune function.
- ICS offers a promising strategy to improve outcomes by addressing both tumor burden and the host immune response.